Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with
the protocol increasing doses of AT13387 are given to patients with advanced cancer who do
not have alternative treatment options. The preferred dose of AT13387 will be identified
according to the side effects experienced at different dose levels.